Clinical Trial Update: Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1 [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating afuresertib in combination with sintilimab and chemotherapy in selected solid tumors resistant to prior PD-1/PD-L1 therapy; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Endometrial Cancer
• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Afuresertib (afuresertib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Laekna Limited | Conditions: Solid Tumor, NSCLC | Phase 1, Phase 2 | Status: COMPLETED